原位杂交评估 miR-155 在非小细胞肺癌中的预后影响。
Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization.
机构信息
Department of Oncology, University Hospital of North Norway, Tromso, Norway.
出版信息
J Transl Med. 2011 Jan 10;9:6. doi: 10.1186/1479-5876-9-6.
BACKGROUND
In recent years, microRNAs (miRNAs) have been found to play an essential role in tumor development. In lung tumorigenesis, targets and pathways of miRNAs are being revealed, and further translational research in this field is warranted. MiR-155 is one of the miRNAs most consistently involved in various neoplastic diseases. We aimed to investigate the prognostic impact of the multifunctional miR-155 in non-small cell lung cancer (NSCLC) patients.
METHODS
Tumor tissue samples from 335 resected stage I to IIIA NSCLC patients were obtained and tissue microarrays (TMAs) were constructed with four cores from each tumor specimen. In situ hybridization (ISH) was used to evaluate the expression of miR-155.
RESULTS
There were 191 squamous cell carcinomas (SCCs), 95 adenocarcinomas (ACs), 31 large cell carcinomas and 18 bronchioalveolar carcinomas. MiR-155 expression did not have a significant prognostic impact in the total cohort (P = 0.43). In ACs, high miR-155 expression tended to a significant negative prognostic effect on survival in univariate analysis (P = 0.086) and was an independent prognostic factor in multivariate analysis (HR 1.87, CI 95% 1.01 - 3.48, P = 0.047). In SCC patients with lymph node metastasis, however, miR-155 had a positive prognostic impact on survival in univariate (P = 0.034) as well as in multivariate (HR 0.45, CI 95% 0.21-0.96, P = 0.039) analysis.
CONCLUSIONS
The prognostic impact of miR-155 depends on histological subtype and nodal status in NSCLC.
背景
近年来，人们发现 microRNAs（miRNAs）在肿瘤发生发展中发挥着重要作用。在肺癌发生过程中，miRNAs 的靶点和通路正在被揭示，这一领域的进一步转化研究是合理的。miR-155 是涉及各种肿瘤性疾病的 miRNA 之一。我们旨在研究多功能 miR-155 在非小细胞肺癌（NSCLC）患者中的预后影响。
方法
收集 335 例 I 至 IIIA 期 NSCLC 患者的肿瘤组织标本，构建组织微阵列（TMA），每个肿瘤标本取 4 个核心。采用原位杂交（ISH）检测 miR-155 的表达。
结果
191 例为鳞癌（SCC），95 例为腺癌（AC），31 例为大细胞癌，18 例为细支气管肺泡癌。miR-155 表达在总队列中无显著预后影响（P=0.43）。在 AC 中，miR-155 高表达在单因素分析中倾向于显著的生存负预后作用（P=0.086），且在多因素分析中是独立的预后因素（HR 1.87，95%CI 1.01-3.48，P=0.047）。然而，在有淋巴结转移的 SCC 患者中，miR-155 在单因素（P=0.034）和多因素（HR 0.45，95%CI 0.21-0.96，P=0.039）分析中均对生存有正预后作用。
结论
miR-155 的预后影响取决于 NSCLC 的组织学亚型和淋巴结状态。
Zotero 插件